Expanded Access to Tipifarnib

Kura Oncology, Inc.

Overview

Requests for single patient expanded access to tipifarnib may be considered for adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL). To request access, use Responsible Party contact information provided in this record. Expanded access for tipifarnib is only available in the United States.

Study Type

EXPANDED_ACCESS

Conditions

HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)

Interventions

TipifarnibDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion/Exclusion Criteria: Diagnosed with HRAS-mutant carcinomas or peripheral T Cell Lymphoma (PTCL). Adult, ages 18+. Have exhausted appropriate standard treatments without success and no comparable or satisfactory alternative treatment is available or exists to treat the disease or condition. Is ineligible for participation in any ongoing clinical study of the investigational drug, which includes lack of access due to geographic limitations. Meets any other pertinent medical criteria for access to the investigational drug, as established by the Kura Oncology

Central Contacts

Clinical Operations

CONTACT

617-588-3755 ExpandedAccess@kuraoncology.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.